Evidence map›Paper›PMID 40569506›Full record

ArticleBreast cancer research and treatment2025

Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.

Mandeep Kaur, Astrid Quirarte, Amy M Shui, Anna Vertido, Elle Clelland, Harriet Rothschild, Laura J Esserman, Cheryl Ewing, Rita A Mukhtar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mandeep KaurSchool of Medicine, University of California, San Francisco, CA, USA.
Astrid QuirarteDivision of Surgical Oncology, Department of Surgery, University of California, 1825 4Th Street, 3Rd Floor, Box 1710, San Francisco, CA, 94143, USA.
Amy M ShuiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Anna VertidoDivision of Surgical Oncology, Department of Surgery, University of California, 1825 4Th Street, 3Rd Floor, Box 1710, San Francisco, CA, 94143, USA.
Elle ClellandSchool of Medicine, University of California, San Francisco, CA, USA.
Harriet RothschildSchool of Medicine, University of California, San Francisco, CA, USA.
Laura J EssermanDivision of Surgical Oncology, Department of Surgery, University of California, 1825 4Th Street, 3Rd Floor, Box 1710, San Francisco, CA, 94143, USA.
Cheryl EwingDivision of Surgical Oncology, Department of Surgery, University of California, 1825 4Th Street, 3Rd Floor, Box 1710, San Francisco, CA, 94143, USA.
Rita A MukhtarDivision of Surgical Oncology, Department of Surgery, University of California, 1825 4Th Street, 3Rd Floor, Box 1710, San Francisco, CA, 94143, USA. rita.mukhtar@ucsf.edu.

Funding

Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
NCI NIH HHS K08 CA256047NCI NIH HHS K08CA256047
6 · The paper itself

Abstract

purposeWhile the impact of socioeconomic factors on breast cancer diagnosis, treatment, and outcomes are well-documented, few studies have focused on invasive lobular carcinoma (ILC), the second most common type of breast cancer. We evaluated the relationships between race and socioeconomic status (SES) with clinicopathological characteristics and outcomes in patients with stage I-III ILC using the National Cancer Database (NCDB).

methodsWe used the NCDB, a national oncology database, to evaluate insurance status, a composite measure of SES (education and income), clinicopathological characteristics, and outcomes in patients with stage I-III ILC. Clinicopathologic variables included tumor size, presence of lymphovascular invasion (LVI), and tumor receptor subtype (hormone receptor, HR), and tumor grade. Overall survival was analyzed with multivariable Cox proportional hazards models.

resultsWe identified 269,657 patients with stage I-III ILC. Patients in the Medicaid/no insurance group and those with lower SES had larger tumors, more positive lymph nodes, fewer HR+ tumors, and higher-grade tumors. Those in the low SES group had higher rates of chemotherapy use and, in those with HR+ tumors, lower rates of endocrine therapy use. In a multivariable model adjusting for SES, self-identified race/ethnicity, age, stage, receptor subtype, grade, treatment, and Charlson-Deyo score, patients with low SES had a 24% higher risk of death by 5 years compared to patients with high SES (HR 1.24, 95% CI 1.19-1.30, p < 0.001).

conclusionWhile our study confirms several known disparities in the presentation, outcomes, and treatment of breast cancer, this is the first evaluation to assess how different components of SES influence ILC specifically.

Indexed as

Breast NeoplasmsCarcinoma, LobularSocial ClassAdultAgedDatabases, FactualFemaleHumansMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisSocioeconomic FactorsTreatment OutcomeUnited StatesBreast cancer outcomesInsuranceInvasive lobular carcinomaSocioeconomic status

Identifiers

PMID40569506
PMCPMC12259733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.